Abstract:The Bayesian optimal interval (BOIN) design is a novel phase I trial design for finding the maximum tolerated dose (MTD). It can be used to conduct both single-agent and drug-combination trials. The BOIN design is motivated by the top priority and concern of clinicians, which is to effectively treat patients and minimize the chance of exposing them to subtherapeutic or overly toxic doses. The most important advantage of the BOIN design is that it is easy to implement in practice and has superior operating characteristics. The BOIN design is algorithm-based and thus can be implemented in a way similar to the traditional “3+3” design. The performance of the BOIN design is comparable to that of the continual reassessment method (CRM, one of the best performing model-based phase I trial designs) in terms of selecting the MTD, but has a lower risk of assigning patients to subtherapeutic or overly toxic doses (i.e., better patient ethics). The idea behind the BOIN design is straightforward. The conduct of phase I trials can be viewed as a sequence of decision-making steps of dose assignment for patients who are sequentially enrolled into a trial. At each moment of decision making, based on the observed data, we take one of three actions: escalate, deescalate or retain the current dose. Under the standard assumption that efficacy monotonically increases with toxicity (for cytotoxic agents), an ideal trial design would escalate the dose when the current dose is below the MTD in order to avoid treating a patient at a subtherapeutic dose level; deescalate the dose when the current dose is above the MTD in order to avoid exposing a patient to an overly toxic dose; and retain the same dose level when the current dose is equal (or close) to the MTD. However, such an ideal design is not available in practice because we do not know whether the current dose is actually below, above or equal (or close) to the MTD, and need to

Sequential Continual Reassessment Method for Two-Dimensional Dose Finding.

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Local Continual Reassessment Methods for Dose Finding and Optimization in Drug-Combination Trials.

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Adaptive Dose Modification for Phase I Clinical Trials

Dynamic Ordering Design for Dose Finding in Drug‐combination Trials

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

A Dose-Finding Design for Phase I Clinical Trials Based on Bayesian Stochastic Approximation

Adaptive two-stage seamless sequential design for clinical trials

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

A new function for drug combination dose finding trials

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

Robust EM Continual Reassessment Method in Oncology Dose Finding